Rifabutin, used to treat HIV-infected tuberculosis, shows highly variable drug exposure, complicating dosing. Effects of SLCO1B1 polymorphisms on rifabutin pharmacokinetics were investigated in 35 African HIV-infected tuberculosis patients after multiple doses. Nonlinear mixed-effects modeling found that influential covariates for the pharmacokinetics were weight, sex, and a 30% increased bioavailability among heterozygous carriers of SLCO1B1 rs1104581 (previously associated with low rifampin concentrations). Larger studies are needed to understand the complex interactions of host genetics in HIV-infected tuberculosis patients. (This study has been registered at ClinicalTrials.gov under registration no. NCT00640887.).
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4704238 | PMC |
| http://dx.doi.org/10.1128/AAC.01195-15 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Magnitude of opportunistic infections and associated factors among HIV-infected individuals attending care and treatment clinics in Dar es Salaam, Tanzania: a hospital-based cross-sectional study.
BMJ Open
January 2025
Department of Microbiology and Immunology, Muhimbili University of Health and Allied Sciences, Dar es Salaam, United Republic of Tanzania.
Objectives: This study aims to assess the magnitude of opportunistic infection (OI) and to identify factors associated with OIs among people living with HIV (PLHIV) on antiretroviral treatment (ART), attending HIV care and treatment clinics.
Design: A hospital-based cross-sectional study.
Setting: The study was conducted at Muhimbili National Hospital, Mwananyamala and Temeke Regional Referral Hospitals, in Dar es Salaam, Tanzania.
The prognosis for delayed immune recovery in HIV-infected children might be associated with pre-cART CD4 T cell count irrespective of co-infection with tuberculosis.
BMC Res Notes
January 2025
Ragon Institute of MGH, MIT, and Harvard, 600 Main Street, Cambridge, MA, 02139, USA.
Background: Immune reconstitution following the initiation of combination antiretroviral therapy (cART) significantly impacts the prognosis of individuals infected with human immunodeficiency virus (HIV). Our previous studies have indicated that the baseline CD4 T cells count and percentage before cART initiation are predictors of immune recovery in TB-negative children infected with HIV, with TB co-infection potentially causing a delay in immune recovery. However, it remains unclear whether these predictors consistently impact immune reconstitution during long-term intensive cART treatment in TB-negative/positive children infected with HIV.
View Article and Find Full Text PDF[Exploring the mechanism of HIV infection on T lymphocyte mitochondrial damage based on MAPK pathway].
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi
December 2024
Department of Infection and Immunology, Changsha First Hospital, Changsha 410005, China.
Objective To clarify the mechanism that HIV infection mediates mitochondrial damage of CD4 T lymphocytes (CD4 T cells) through mitogen-activated protein kinase (MAPK) pathway. Methods From October 1st, 2022 to March 31st, 2023, 47 HIV-infected people who received antiretroviral therapy (ART) for 4 years were recruited, including 22 immune non-responders (INR) and 25 responders (IR); and 26 sex and age-matched control participants (HC) who were negative for HCV, HBV, and HIV infections. The immune parameters were analyzed by flow cytometry.
View Article and Find Full Text PDFThe value of metagenomic next-generation sequencing with blood samples for the diagnosis of disseminated tuberculosis.
Front Cell Infect Microbiol
December 2024
Department of Infectious Diseases, the Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
Objective: The aim of this study was to assess the clinical value of metagenomic next-generation sequencing (mNGS) of blood samples for the identification of disseminated tuberculosis (DTB).
Methods: A total of 48 individuals suspected of DTB were enrolled. All patients underwent mNGS of peripheral blood and conventional microbiological tests.
Prevalence of TB-related symptoms and self-reported disability among adult TB survivors.
IJTLD Open
December 2024
College of Public Health, Global Health Institute, University of Georgia, Athens, GA, USA.
Background: Growing evidence suggests that post-TB-related morbidity occurs often among TB survivors, but there is limited epidemiological data on the burden of symptoms and disability after successful completion of treatment. We evaluated the prevalence of TB-related symptoms, self-reported disability, and factors associated with disability among adult TB survivors who recently completed treatment in Uganda.
Methods: Between January 2022 and October 2023, we conducted a study of adults who completed treatment for drug-susceptible TB in Kampala, Uganda.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!